id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S7981 R24256 |
Coste (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2020 | Neonatal condition | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Controls: mixed indications |
0.85 [0.42;1.71] C excluded (control group) |
9/84 349/2,813 | 358 | 84 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7809 R23147 |
Coste (Phenobarbital) (Controls unexposed, NOS), 2020 | Neonatal condition | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 0.80 [0.40;1.60] C | 9/84 222,201/1,710,441 | 222,210 | 84 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6686 R18636 |
D'Souza (Phenobarbital) (Controls unexposed, disease free), 1991 | Neonatal conditions | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
1.22 [0.06;26.35] C excluded (control group) |
0/4 6/62 | 6 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6694 R18797 |
D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 | Neonatal conditions | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.31 [0.01;8.68] C | 0/4 2/8 | 2 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 0.77 [0.39;1.52] | 222,212 | 88 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed, NOS; 2: Phenobarbital) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6686, 7981